GlassScriptPhysician profile
James V Tran
NPI 1598781346
$35,368.42
in general payments reported to CMS, 2019-2025
41 companies · $7,585 in 2025
The $7,585 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,998 · 2021: $3,670 · 2022: $2,976 · 2023: $3,472 · 2024: $2,679 · 2025: $7,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,691 · Consulting Fee: $3,576 · Travel and Lodging: $460 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,691.21 |
| Consulting Fee | $3,576.00 |
| Travel and Lodging | $459.63 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,623.16 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $5,779.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $3,348.30 | 2019-2025 | Farxiga, Airsupra, Andexxa |
| Janssen Pharmaceuticals, INC | $1,998.06 | 2019-2024 | Xarelto |
| Amgen INC. | $1,570.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Gilead Sciences, INC. | $1,207.71 | 2019-2025 | Vemlidy |
| Amarin Pharma, INC. | $1,136.70 | 2019-2023 | |
| Abbvie INC. | $934.22 | 2019-2025 | Viberzi, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $929.49 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $896.82 | 2019-2025 | Lifevest |
| Ironwood Pharmaceuticals, INC | $884.73 | 2019-2025 | Linzess |
| Novo Nordisk INC | $740.37 | 2021-2025 | Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $633.15 | 2021-2025 | Verquvo, Belsomra, Januvia |
| E.R. Squibb & Sons, L.L.C. | $396.31 | 2019-2025 | Camzyos, Eliquis |
| Phathom Pharmaceuticals, INC. | $372.57 | 2024-2025 | Voquezna |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.